title: Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome.
abstract: BACKGROUND
  Only 30% to 40% of patients with Zollinger-Ellison syndrome (ZES) undergoing operation with curative intent have biochemical cures. The purpose of this analysis was to identify perioperative factors associated with long-term (> or = 5 years) biochemical cures.
  
  
  METHODS
  From December 1981 to September 1997, 128 patients with potentially curable ZES underwent 152 abdominal explorations with resection of all identifiable disease. Of these, 31 outcomes were identified with documented cures at > or = 5 years from operation and were compared with outcomes of 110 patients who were not cured. Univariate and multivariate statistical analyses were performed.
  
  
  RESULTS
  The results of a normal immediate postoperative fasting serum gastrin and secretin stimulation test were significantly and independently correlated with 5-year cure (P2 = .005 and .0099, respectively). A diagnosis of multiple endocrine neoplasia type 1 was significantly inversely correlated with cure on univariate analysis (P2 = .027). Gender, age, duration of symptoms, results of diagnostic tests, or results of imaging studies did not correlate with outcome.
  
  
  CONCLUSIONS
  All patients with sporadic potentially curable ZES should undergo exploration because outcome is not associated with preoperative tests. Only 5% of patients with ZES and multiple endocrine neoplasia type 1 were cured at 5 years. A normal fasting serum gastrin or secretin stimulation value value immediately postoperatively provides important prognostic information.
authors.affiliation: Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Richard_Alexander@nih.gov
authors.forename: H R
authors.initials: HR
authors.lastname: Alexander
authors.forename: D L
authors.initials: DL
authors.lastname: Bartlett
authors.forename: D J
authors.initials: DJ
authors.lastname: Venzon
authors.forename: S K
authors.initials: SK
authors.lastname: Libutti
authors.forename: J L
authors.initials: JL
authors.lastname: Doppman
authors.forename: D L
authors.initials: DL
authors.lastname: Fraker
authors.forename: J A
authors.initials: JA
authors.lastname: Norton
authors.forename: F
authors.initials: F
authors.lastname: Gibril
authors.forename: R T
authors.initials: RT
authors.lastname: Jensen
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000150:complications; D015999:Multivariate Analysis; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome; D015043:Zollinger-Ellison Syndrome / Q000097:blood / Q000150:complications / Q000601:surgery*